Business Context and Reporting Period
This Form 6-K filing by Alcon, Inc. (a Swiss corporation) reports unaudited financial results for the three-month and six-month periods ended June 30, 2002. The filing incorporates by reference the company's interim financial statements and Management's Discussion and Analysis (MD&A). A significant corporate event during this period was Alcon's Initial Public Offering (IPO) in March 2002, following its separation from parent company Nestlé S.A. The company operates in two primary segments: Alcon United States and Alcon International, focusing on pharmaceuticals, surgical equipment, and consumer eye care products.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended June 30, 2002 | 3 Months Ended June 30, 2001 | 6 Months Ended June 30, 2002 | 6 Months Ended June 30, 2001 |
|---|---|---|---|---|
| Sales | $809.5 | $745.9 | $1,516.0 | $1,400.7 |
| Gross Profit | $575.0 | $526.7 | $1,071.1 | $997.0 |
| Gross Margin % | 71.0% | 70.6% | 70.7% | 71.2% |
| Operating Income | $236.9 | $176.0 | $388.5 | $328.1 |
| Net Earnings | $162.8 | $103.1 | $256.8 | $187.5 |
| Diluted EPS | $0.53 | $0.34 | $0.87 | $0.63 |
| Cash from Operations (6mo) | $255.3 | $207.7 | ||
| Cash & Equivalents (End of Period) | ||||
| Short-Term Borrowings | $1,303.7 | $805.5 | $1,303.7 | $805.5 |
| Long-Term Debt (Net) | $90.1 | $697.4 | $90.1 | $697.4 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 8.5% year-over-year for the quarter and 8.2% for the six-month period. Growth was driven primarily by the pharmaceutical segment, particularly the launch of TRAVATAN® and growth in Patanol®. Constant currency sales growth was higher (8.9% for the quarter) due to a negative currency impact from the strong U.S. dollar.
- Profitability: Net earnings surged 57.9% for the quarter and 37.0% for the six-month period. Operating income increased 34.6% for the quarter, aided by a $10.7 million benefit from the adoption of FASB Statement 142 (elimination of goodwill amortization).
- Capital Structure: The company underwent a major capital restructuring. Proceeds from the IPO ($2,188.1 million) were used to redeem preferred shares held by Nestlé ($2,188.0 million) and repay short-term debt. Consequently, long-term debt decreased significantly from $697.4 million to $90.1 million, while short-term borrowings increased to $1,303.7 million to manage liquidity during the transition.
- Cash Position: Cash and cash equivalents dropped from $1,140.5 million at year-end 2001 to $148.0 million at June 30, 2002, primarily due to the redemption of preferred shares and dividend payments to Nestlé.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted strong performance in pharmaceuticals and surgical products (specifically IOLs). However, refractive product sales declined due to weak consumer confidence and the elective nature of the procedures. Management noted that the effective tax rate decreased to 32.3% (quarter) and 32.5% (six months) due to favorable tax settlements and accounting changes.
Unusual Items:
- Deferred Compensation: A one-time charge of $22.6 million ($14.2 million net of tax) was recorded in operating income related to changes in the deferred compensation plan in connection with the IPO.
- Accounting Changes: Adoption of FASB Statement 142 eliminated goodwill amortization, improving reported operating income by $10.7 million for the quarter and $21.3 million for the six-month period compared to the prior year.
Risks and Contingencies:
- Currency Risk: The company is exposed to foreign exchange fluctuations, which negatively impacted sales growth. A 10% depreciation in non-U.S. dollar currencies could decrease pre-tax earnings by approximately $16.2 million.
- Interest Rate Risk: With a majority of debt being short-term floating-rate, a 1% increase in rates would decrease pre-tax earnings by $11.5 million.
- Market Risks: Sales in Japan and Argentina declined due to currency losses and pricing pressures. Refractive surgery volumes remain sensitive to economic conditions.
- Litigation: The company faces various legal proceedings, including product liability and patent infringement, though management believes current liabilities are adequately estimated.
Investor Verification Checklist
- Debt Composition: Verify the sustainability of the $1.3 billion in short-term borrowings and the reliance on commercial paper facilities ($608.1 million outstanding) following the IPO.
- Adjusted Earnings: Review "Adjusted Net Earnings" excluding goodwill amortization and one-time deferred compensation charges to assess core operational performance.
- Refractive Segment: Monitor the recovery of refractive product sales, which are currently depressed due to consumer confidence issues.
- Currency Hedging: Assess the effectiveness of forward contracts in mitigating the impact of the strong U.S. dollar on international sales.
- Goodwill Impairment: Confirm that the adoption of FASB 142 did not result in any immediate goodwill impairment charges, as noted in the filing.